Evidence map›Paper›PMID 38585442›Full record

ArticleNeurology. Clinical practice2024

Understanding Health Care Provider Burnout When Caring for Patients With Refractory Epilepsy in the United States.

Mei Lu, Enrico Speri, A Lauks, Charles Leibson, Satish C Rao

Abstract read
In one paragraph

Article in Neurology. Clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mei LuTakeda Pharmaceuticals USA, Inc. (ML, SCR), Lexington, MA; and IQVIA (ES, AL, CL), Cambridge, MA.ORCID https://orcid.org/0000-0003-3764-8401
Enrico SperiTakeda Pharmaceuticals USA, Inc. (ML, SCR), Lexington, MA; and IQVIA (ES, AL, CL), Cambridge, MA.ORCID https://orcid.org/0009-0009-7538-9755
A LauksTakeda Pharmaceuticals USA, Inc. (ML, SCR), Lexington, MA; and IQVIA (ES, AL, CL), Cambridge, MA.ORCID https://orcid.org/0009-0009-4563-4879
Charles LeibsonTakeda Pharmaceuticals USA, Inc. (ML, SCR), Lexington, MA; and IQVIA (ES, AL, CL), Cambridge, MA.ORCID https://orcid.org/0009-0008-6858-3624
Satish C RaoTakeda Pharmaceuticals USA, Inc. (ML, SCR), Lexington, MA; and IQVIA (ES, AL, CL), Cambridge, MA.ORCID https://orcid.org/0009-0001-2090-167X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Among health care providers (HCPs), neurologists have one of the highest rates of burnout in the United States, compromising the quality and accessibility of patient care. Patients with refractory epilepsy are especially challenging to treat. This study aims to understand the burnout level in neurologists treating patients with refractory epilepsy and identify key contributing factors. Methods: US board-certified pediatric/adult neurologists who devote ≥50% of their time to clinical practice and treat ≥10 unique patients with refractory epilepsy annually were invited to take a noninterventional quantitative survey, designed to capture key elements of the HCP's background, burnout level, current practice, burden domains, and satisfaction with current antiseizure medications (ASMs). Burnout in 3 domains (emotional exhaustion, depersonalization, and personal accomplishment) was assessed by the validated Maslach Burnout Inventory-Human Services Survey. Results: From March 11, 2022, to April 10, 2022, a total of 138 neurology-specialist HCPs participated in the survey, divided between adult epileptologists (n = 44), adult neurologists (n = 41), pediatric epileptologists (n = 36), and pediatric neurologists (n = 17). Of participating HCPs, 61% experienced at least some burnout (≥1 of 3 burnout domains categorized as Discussion: Some burnout is common among HCPs who treat patients with refractory epilepsy. However, management of refractory epilepsy is challenging, and satisfaction with available ASMs is low. Thus, addressing these contributing factors may help to alleviate HCP burnout.

Identifiers

PMID38585442
PMCPMC10996904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.